Engitix Therapeutics

On World Cancer Research Day, it is important to recognise the profound impact of cancer worldwide. Cancer is the second leading cause of death, accounting for approximately 10 million deaths in 2020. At Engitix, we are committed to driving innovation in cancer research, with a focus on primary and metastatic gastrointestinal tumours. We are harnessing the power of the extracellular matrix (ECM), a key component of the tumour microenvironment and player in tumour progression, which has been often overlooked in drug discovery research. By leveraging Engitix's cutting-edge ECM technology, we are able to better understand disease biology, identify and validate more relevant drug targets and more accurately predict the efficacy of potential therapeutics. #WorldCancerResearchDay #CancerResearch #THEECMcompany #DrugDiscovery 

In the midst of a busy year, we took a moment to regroup and celebrate our company anniversary during Engitix Therapeutics annual team offsite event!   Between rounds of mini golf, we participated in workshops led by some of our leaders focusing on this year’s theme “teamwork” with a spotlight on effective communication, collaboration, motivation, and trust. The day was filled with team-building activities and a touch of healthy competition! A special shoutout to the Top Ballers team, who were voted overall winners by our workshop organisers and to Filippo Prestinoni Bocca – who, it turns out, is not just a talent in science but a mini golf champion too!   The real win was quality time with the team and plenty of laughter. Here's to more moments like this and a strong finish to the year. Kudos to the entire team for making it such a memorable day, once again! ⛳ 🔬   #teambuilding #relationships #fun #biotech #THEECMcompany

In the midst of a busy year, we took a moment to regroup and celebrate our company anniversary during Engitix Therapeutics annual team offsite event!   Between rounds of mini golf, we participated in workshops led by some of our leaders focusing on this year’s theme “teamwork” with a spotlight on effective communication, collaboration, motivation, and trust. The day was filled with team-building activities and a touch of healthy competition! A special shoutout to the Top Ballers team, who were voted overall winners by our workshop organisers and to Filippo Prestinoni Bocca – who, it turns out, is not just a talent in science but a mini golf champion too!   The real win was quality time with the team and plenty of laughter. Here's to more moments like this and a strong finish to the year. Kudos to the entire team for making it such a memorable day, once again! ⛳ 🔬   #teambuilding #relationships #fun #biotech #THEECMcompany

A massive thank you to Kevin Harris for delivering an inspirational talk to our team a few weeks ago! With over 25 years of experience, Kevin has a remarkable track record in launching and commercialising therapeutics while building patient-centric organisations. He emphasises that "ultimate success is measured by the people you impact". Kevin most recently served as the Chief Commercial Officer of VectivBio, joining the company in November 2019 and continuing through its acquisition by Ironwood Pharmaceuticals in June 2023. As a pre-clinical biopharma company, we’re reminded of the importance of a comprehensive strategy that spans the entire lifecycle of a biotech product. Kevin’s insights into the critical stages of drug development underscore the significance of each phase in ensuring a successful product launch and commercialisation: Learn, Plan, Prepare, Go!   His experience in navigating regulatory approvals, scaling up manufacturing, and driving commercialisation have provided invaluable lessons for our team. We’re inspired to apply these insights as we advance our therapeutic candidates to make a meaningful impact on patients' lives.   #Biotech #Leadership #BioPharma #Healthcare #Innovation #PatientFirst

Come hear our CEO and Co-founder Giuseppe Mazza at the Basic Science Retreat today at 5pm, where he’ll be sharing his journey from academia to the exciting world of biotech! Stick around afterwards for a roundtable discussion at 6pm, where he'll dive into the conversation with other experts in the field.   #Biotech #Academia #ECM #TheECMCompany #Engitix #Fibrosis #SolidTumours #BasicScienceRetreat2024

Congratulations to our interns! This summer, we once again welcomed enthusiastic students to experience the biotech world. Their fresh perspectives and energy were inspiring, and we're glad they had a great experience. 🥼🧪🔬👩🔬 We're currently hiring for several positions – reach out now to learn more. #Biotech #ECM #EngitixTherapeutics #Hiring #Inspiring 

We are delighted to announce the appointments of Adrian Ray and Scott Turner as Scientific Advisors. Dr Giuseppe Mazza CEO said: “We are pleased to welcome Dr Adrian Ray and Dr Scott Turner, as new scientific advisors. Their combined industry insights, strong translational science and small molecule and biologic drug discovery experience across cancer and fibrosis will enhance our R&D efforts. Their strategic guidance will be invaluable as we continue to advance discoveries from our proprietary ECM platform technologies into transformational therapies for patients with fibrosis and solid tumours.” Dr Adrian Ray has over two decades of experience in biotech working at Gilead, Nimbus, Morphic and, most recently, serving as Chief Scientific Officer at Third Harmonic Bio. He has provided leadership for small molecule drug discovery, nonclinical development and translation across therapeutic areas contributing to numerous IND and successful worldwide registrational filings. Dr Scott Turner is currently the Chief Scientific Officer at Arda Therapeutics. Prior to joining Arda, Scott served as CSO at Pliant Therapeutics, where he played a pivotal role in the creation of Pliant's fibrosis discovery platform and spearheaded the development of their anti-fibrotic pipeline. His innovative approaches, including pioneering the use of single-cell data to dissect drug mechanisms of action and driving an advanced biomarker strategy, led to remarkable successes in achieving clinical proof of concept. Prior to Pliant, Dr Turner led research and development at KineMed Inc. a platform technology company developing translational biomarkers in fibrosis and metabolic disease. Scott and Adrian join our strong advisory network of renowned global academics and clinical leaders specialising in diseases of the gastrointestinal system, skin and lung fibrosis, and cancers. Current scientific advisors also include Massimo Pinzani, Alexey "Alex" Lugovskoy, Doug Thorburn, Emmanuel Tsochatzis, Tu Vinh Luong, Antonio Di Sabatino, Hendrik-Tobias Arkenau & Giuseppe Kito Fusai. See the full press release HERE: https://lnkd.in/eNdR_uGs #ScientificAdvisors #EngitixTherapeutics #DrugDiscovery #ECM

Copenhagen will host the ECM2024 Pharmacology Congress next week, featuring a great program and speakers' lineup focused on exciting updates about the role of ECM in various disorders and its potential as a source of therapeutic targets and biomarkers. We are thrilled to have our CEO Giuseppe Mazza present Engitix Therapeutics’ work on decoding our unique ECM platform to develop novel therapies for fibrosis and solid tumours. Join him next Monday at 1:10PM CEST! #ECM #TheECMCompany #ECM2024 #fibrosis #solidtumours

We're excited for Alan Holmes, our VP of Translational Biology, to be presenting at the EASL the home of Hepatology symposium in Milan later today. Reach out to him to learn more about Engitix!

We are excited about the journey so far and are very much looking forward to what’s coming next as we head towards pre-clinical development! Find out more about Engitix's mission to develop therapies for patients with fibrosis and cancer. Take an in-depth look into our research, which involves our world-leading ECM platform, passionate team, and impactful discovery projects, through our new introduction video. 📽 🔬 #EngitixTherapeutics #DrugDiscovery #ECM #Team https://lnkd.in/eHmMaRCq